-
ShuWen Biotech’s Preeclampsia Self-Test Receives NMPA Approval, Marking a Global First
•
Zhejiang-based ShuWen Biotech Co., Ltd has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its innovative CercaTest Red, a patented self-test designed for household use by pregnant women to screen for preeclampsia. This marks the first time a self-test of this kind has…
-
ShuWen Biotech’s MammaTyper Diagnostic Kit Receives NMPA Approval for Breast Cancer Molecular Classification
•
ShuWen Biotech Co., Ltd, a biopharmaceutical company based in Zhejiang, has announced that its MammaTyper diagnostic kit has received market approval from the National Medical Products Administration (NMPA). The kit is intended for use in cases where immunohistochemistry (IHC) results are indeterminate or unsatisfactory, or when the IHC outcome significantly…
-
Shuwen Biotech’s Subsidiary Signs Promotion Agreement with Sysmex Europe for Breast Cancer Detection Product
•
China-based diagnostic specialist Shuwen Biotech Co., Ltd announced that its wholly-owned German subsidiary, Cerca Biotech GmbH, has entered into a promotion agreement with Japanese firm Sysmex Corporation’s German unit, Sysmex Europe SE. Under the terms of the deal, Sysmex will promote and distribute Cerca’s MammaTyper, a breast cancer detection product…
-
Shuwen Biotech Partners with Nottingham University Hospitals for MammaTyper
•
China – based diagnostic specialist Shuwen Biotech Co., Ltd and its German wholly – owned subsidiary Cerca Biotech GmbH have entered into a collaboration agreement with Nottingham University Hospitals (NUH). The agreement is designed to bolster the clinical study, application, and promotion of Shuwen’s core product, MammaTyper. Financial details of…
